Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
obicetrapib + ezetimibe
- Development stage
- Unknown
- Lead developer
- NewAmsterdam Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Obicetrapib + ezetimibe is a fixed-dose combination of two oral small molecule lipid-lowering agents under development for the treatment of dyslipidemia and hypercholesterolemia. Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting CETP, leading to increased hepatic LDL receptor expression and enhanced LDL clearance. Ezetimibe inhibits the Niemann-Pick C1-Like 1 protein (NPC1L1), reducing intestinal absorption of cholesterol. The combination has demonstrated robust reductions in LDL-C and other atherogenic lipids when used as adjunctive therapy to statins in patients with cardiovascular disease or familial hypercholesterolemia who are not adequately controlled on standard therapies. Developed by NewAmsterdam Pharma, the fixed-dose formulation has reached Phase 3 clinical trials, including the pivotal TANDEM study[4][5][7][8].
- Other names
- obicetrapib/ezetimibe
02
Targets
CETPNPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on obicetrapib + ezetimibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on obicetrapib + ezetimibe.